204 related articles for article (PubMed ID: 21121175)
1. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Pappa S; Tsouli S; Apostolou G; Mavreas V; Konitsiotis S
Clin Neuropharmacol; 2010; 33(6):271-5. PubMed ID: 21121175
[TBL] [Abstract][Full Text] [Related]
2. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
3. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
4. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.
Angus S; Sugars J; Boltezar R; Koskewich S; Schneider NM
J Clin Psychopharmacol; 1997 Apr; 17(2):88-91. PubMed ID: 10950469
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
7. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
Caroff SN; Walker P; Campbell C; Lorry A; Petro C; Lynch K; Gallop R
J Clin Psychiatry; 2007 Mar; 68(3):410-5. PubMed ID: 17388711
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
Libov I; Miodownik C; Bersudsky Y; Dwolatzky T; Lerner V
J Clin Psychiatry; 2007 Jul; 68(7):1031-7. PubMed ID: 17685739
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
10. Treatment of tardive dyskinesia with donepezil: a pilot study.
Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
[TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
12. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
13. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
[TBL] [Abstract][Full Text] [Related]
14. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
15. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
[TBL] [Abstract][Full Text] [Related]
17. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Woods SW; Saksa JR; Baker CB; Cohen SJ; Tek C
J Clin Psychiatry; 2008 Apr; 69(4):546-54. PubMed ID: 18312060
[TBL] [Abstract][Full Text] [Related]
18. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
[TBL] [Abstract][Full Text] [Related]
20. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]